The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia-Reference-Cited by-同舟云学术

The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia

Published:2017-10 Issue: Volume:61 Page:84-88
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Wang Fang,Jia Jin-Song,Wang Jing,Zhao Ting,Jiang Qian,Jiang Hao,Zhu Hong-Hu

Funder

National Natural Science Foundation of China

Beijing Municipal Science and Technology Commission of China

national key research and development program of China

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference17 articles.

1. Retinoic acid syndrome: a review;Patatanian;J. Clin. Pharm. Ther.,2008

2. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome;Luesink;Blood,2009

3. Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy;Serefhanoglu;Leuk. Res.,2010

4. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors;Montesinos;Blood,2009

5. Early mortality and the retinoic acid syndrome in acute promyelocytic leukernia: impact of leukocytosis, low-Dose chemotherapy, PMNIRAR-a isoform, and CD13 expression in patients treated with all-trans retinoic acid;Vahdat;Blood,1994

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leucocytosis during induction therapy with all‐trans‐retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment‐related complications;British Journal of Haematology;2024-09-14

2. Early predictor for differentiation syndrome in newly diagnosed acute promyelocytic leukaemia patients treated with single-agent arsenic trioxide;Annals of Hematology;2024-04-29

3. Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group;Blood Cancer Journal;2023-12-05

4. Differentiation syndrome and coagulation disorder — comparison between treatment with oral and intravenous arsenics in pediatric acute promyelocytic leukemia;Annals of Hematology;2023-05-18

5. Long-Term Outcome of Children with Acute Promyelocytic Leukaemia: A Randomised Study of Oral Versus Intravenous Arsenic by SCCLG-APL Group;2023